UPDATE: Cowen Starts Absci Corp. (ABSI) at Market Perform

Cowen analyst Doug Schenkel initiates coverage on Absci Corp. (NASDAQ: ABSI) with a Market Perform rating.

The analyst comments "We are enthused about ABSI's drug creation platform and the potential for meaningful revenue growth as a potentially important enabler in a large and growing biopharma product category. That said, the risk/reward seems balanced at current levels pending more details on partners and platform specs, and more validating milestones."

For an analyst ratings summary and ratings history on Absci Corp. click here. For more ratings news on Absci Corp. click here.

Shares of Absci Corp. closed at $25.01 yesterday.

You May Also Be Interested In

• argenx SE (ARGX) PT Raised to $1,353 at TD Cowen
• Benchmark Reiterates Speculative Buy Rating on Milestone Scientific (MLSS)
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform